Janux Therapeutics, Inc. (NASDAQ:JANX) is Ally Bridge Group NY LLC's 9th Largest Position

Ally Bridge Group NY LLC lowered its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 90,292 shares of the company's stock after selling 18,519 shares during the period. Janux Therapeutics comprises 4.1% of Ally Bridge Group NY LLC's holdings, making the stock its 9th largest position. Ally Bridge Group NY LLC owned approximately 0.17% of Janux Therapeutics worth $4,834,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the last quarter. Avanza Fonder AB bought a new position in Janux Therapeutics during the fourth quarter worth about $139,000. Meeder Asset Management Inc. purchased a new position in shares of Janux Therapeutics in the fourth quarter worth about $159,000. Tower Research Capital LLC TRC lifted its stake in shares of Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after buying an additional 3,436 shares in the last quarter. Finally, Chicago Capital LLC bought a new position in Janux Therapeutics in the 4th quarter worth approximately $230,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Insider Activity at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the transaction, the insider now owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were purchased at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the transaction, the director now directly owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 10,001 shares of company stock worth $313,964 in the last three months. 29.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JANX. Wedbush reaffirmed an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank decreased their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Price Performance

NASDAQ JANX traded down $3.09 on Monday, reaching $29.79. 1,771,446 shares of the company's stock traded hands, compared to its average volume of 851,023. The stock has a market cap of $1.76 billion, a PE ratio of -25.46 and a beta of 3.27. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The stock has a 50-day simple moving average of $29.80 and a 200 day simple moving average of $42.47.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.